Source comparison
FDA Approval vs Research-Grade Tesamorelin
Egrifta received FDA approval in November 2010 specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. A condition where antiretroviral therapy causes abnormal fat distribution, particularly visceral adipose tissue accum
This comparison does not assign a generated winner or score.
- Egrifta received FDA approval in November 2010 specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. A condition where antiretroviral therapy causes abnormal fat distribution, particularly visceral adipose tissue accumulation. The approval was based on two Phase 3 trials (COSMOS and STARS) demonstrating statistically significant VAT reduction and improved trunk-to-peripheral fat ratio in treated groups. FDA-approved Egrifta is manufactured as a lyophilized powder in single-use 1mg or 2mg vials, reconstituted with sterile water for subcutaneous injection. Every batch undergoes potency verification, sterility testing, and endotoxin screening under FDA-mandated Current Good Manufacturing Practice (CGMP) standards.
- Research-grade tesamorelin. Like what's available through Real Peptides and similar suppliers. Is synthesized to the same molecular structure but without FDA batch-level oversight. These formulations are intended for in vitro studies, animal research, or investigational protocols where the peptide's effects are being characterized rather than prescribed for therapeutic use. Quality assurance depends on the supplier: reputable vendors provide third-party purity analysis via high-performance liquid chromatography (HPLC) and mass spectrometry, verifying amino acid sequence accuracy and absence of degradation products.
- The regulatory distinction is non-trivial. Prescription Egrifta can only be dispensed with a valid prescription for its approved indication. Off-label use for athletic performance enhancement or cosmetic fat reduction exists but isn't legally protected. Research-grade tesamorelin occupies a different regulatory space: it's legal to purchase and possess for laboratory research but not for human self-administration outside an IRB-approved study. The FDA's 2022 guidance on research peptides clarified that compounds marketed 'for research use only' must not be promoted with implied or explicit claims of human safety or efficacy. Doing so reclassifies the product as an unapproved drug.